5.28

0.19% -0.010

Pre-market: 5.28

Myriad Genetics Inc (MYGN)

Overview News Price History Option Chain Financials Why MYGN Down? Discussions Forecast Stock Split

Myriad Genetics Inc stock is traded at $5.28, with a volume of 1.37M. It is down -0.19% in the last 24 hours and down -0.38% over the past month. Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Previous Close:

$5.29

Open:

$5.3

24h Volume:

1.37M

Relative Volume:

1.24

Market Cap:

$493.72M

Revenue:

$823.60M

Net Income/Loss:

$-116.00M

P/E Ratio:

-4.0615

EPS:

-1.3

Net Cash Flow:

$-107.30M

1W Performance:

+10.46%

1M Performance:

-0.38%

6M Performance:

-22.24%

1Y Performance:

-49.33%

1-Day Range:

$5.26

$5.485

1-Week Range:

$4.4801

$5.485

52-Week Range:

$3.76

$11.44

Myriad Genetics Inc Stock (MYGN) Company Profile

Name

Myriad Genetics Inc

Sector

Healthcare (1106)

Industry

Diagnostics & Research (52)

Phone

801-584-3600

Address

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Employee

2,700

Twitter

@myriadgenetics

Next Earnings Date

2025-02-24

Latest SEC Filings

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MYGN Myriad Genetics Inc	5.28	494.66M	823.60M	-116.00M	-107.30M	-1.30
TMO Thermo Fisher Scientific Inc	512.69	190.90B	44.56B	6.73B	6.29B	17.74
DHR Danaher Corp	204.73	144.26B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	648.70	50.60B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	120.54	33.67B	6.95B	1.30B	1.15B	4.5696
WAT Waters Corp	319.04	30.62B	3.17B	642.63M	516.49M	10.77

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-21-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
May-08-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-09-25	Downgrade	Guggenheim	Buy → Neutral
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight
Feb-12-25	Initiated	Craig Hallum	Buy
Dec-10-24	Initiated	UBS	Neutral
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Underperform
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform
Dec-21-23	Resumed	Piper Sandler	Neutral
Dec-19-23	Initiated	Wells Fargo	Equal Weight
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Jul-05-23	Resumed	JP Morgan	Underweight
May-23-23	Upgrade	Goldman	Sell → Buy
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform
Oct-06-22	Initiated	Stephens	Equal-Weight
Oct-15-21	Resumed	Cowen	Market Perform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy
Jan-03-19	Initiated	Needham	Strong Buy
Nov-30-18	Upgrade	Goldman	Sell → Neutral
Oct-10-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-11-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-21-18	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-29-18	Initiated	Goldman	Sell
Jan-22-18	Reiterated	Barclays	Equal Weight
Jan-05-18	Initiated	BTIG Research	Buy
Oct-02-17	Resumed	Leerink Partners	Mkt Perform
Aug-09-17	Reiterated	Barclays	Equal Weight
Feb-08-17	Upgrade	Ladenburg Thalmann	Sell → Neutral
Jan-18-17	Initiated	Deutsche Bank	Sell
Oct-10-16	Downgrade	Ladenburg Thalmann	Neutral → Sell

View All

Myriad Genetics Inc Stock (MYGN) Latest News

06:11 AM

Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN - MarketBeat

06:11 AM

Mar 04, 2026

Myriad Genetics Stock Up on New Breast Cancer MRD Test Launch | 2026News and Statistics - IndexBox

Mar 04, 2026

MYGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026

Mar 03, 2026

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz

Mar 03, 2026

Mar 02, 2026

Myriad Commercially Launches Precise MRD with Select Community Oncologists - Bitget

Mar 02, 2026

Myriad Genetics (MYGN) CPO has shares withheld to cover taxes - Stock Titan

Mar 02, 2026

New breast cancer test detects residual disease beyond standard scans - Stock Titan

Mar 02, 2026

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Mar 02, 2026

Feb 28, 2026

Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research - MarketBeat

Feb 28, 2026

MYGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Feb 27, 2026

PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Yahoo Finance

Feb 27, 2026

Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares - MarketBeat

Feb 27, 2026

Insider Buying: Myriad Genetics (NASDAQ:MYGN) Director Acquires 6,100 Shares of Stock - MarketBeat

Feb 27, 2026

S. Louise Phanstiel Acquires 50,407 Shares of Myriad Genetics (NASDAQ:MYGN) Stock - MarketBeat

Feb 27, 2026

Myriad Genetics Insider Bought Shares Worth $494,722, According to a Recent SEC Filing - marketscreener.com

Feb 27, 2026

Director Phanstiel adds 104,507 Myriad Genetics (MYGN) shares - Stock Titan

Feb 27, 2026